HEALTHCARE: Hansen Wins Leadership Award
Diane Hansen, president and CEO of Palomar Health won the CEO of the Year award from The Association of California Healthcare Districts for her leadership and transformation of the North County healthcare district.
BIOTECH: Co. Moves Forward in Mexico, Brazil and the Philippines
INOVIO Pharmaceuticals (NASDAQ: INO), a biotechnology company designing DNA medicines, received approval from Mexico’s national health regulatory agency to advance its COVID-19 vaccine candidate to Phase 3 clinical trials.
BIOTECH: IPO Raises $200M
Cue Health rang the opening bell on the Nasdaq to celebrate its first day as a publicly traded company on Sept. 24. The San Diego-based health technology company, which makes digital diagnostic testing solutions including a COVID-19 molecular test, raised $200 million through its IPO.
MEDICINE: Growing Co. Inks Licensing Deal with Salk Institute and Sanford Burnham Prebys
Endeavor BioMedicines, a clinical-stage precision medicine company, signed an exclusive licensing deal with the Salk Institute for Biological Studies and Sanford Burnham Prebys for a ULK1/2 inhibitor program to broaden the company’s precision oncology pipeline.
BIOTECH: Co. to Remain in S.D.
San Diego-based Agena Bioscience, Inc. agreed to be acquired by Mesa Laboratories, Inc. (NASDAQ:MLAB) for a purchase price of $300 million.
BIOTECH: Firm Invests in RNA Treatments
Replicate Bioscience, a startup developing a pipeline of RNA-based treatments, exited stealth mode on Sept. 8 with $40 million in Series A backing its launch.
BIOTECH: Co. Partners With Research Institute
Jumpcode Genomics, a local genome technology company, has partnered with the Translational Genomics Research Institute (TGen) to help sequence and examine the genomic epidemiology of SARS-CoV-2, the virus that causes COVID-19.
Cue Health will offer 12.5 million common shares for a range of $15 to $17 per share, according to its amended IPO.
BIOTECH: San Diego Co. Joins BICO’s Bioprinting Business
Advanced BioMatrix, a San Diego biotech that creates products for 3D applications including cell cultivation, cell assays and bioprinting, was acquired by BICO Group AB (STO: BICO) for approximately $15 million.